David Burdette, MD
Epilepsy · Grand Rapids, MINPI 1679648315
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $924,228 of the $1,378,262 with a category attached, or 67.1%. 20 manufacturers reported payments, led by UCB, Inc. at 44.6% of the total. Among epilepsy clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,615 payments — averaging $853.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$615K
- Jazz Pharmaceuticals Inc.$228K
- Neuropace, Inc.$193K
- SK Life Science, Inc.$180K
- Greenwich Biosciences, Inc.$93K
- Eisai Inc.$41K
- plus $28K from 14 others
Across 825 payments — averaging $556.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neuropace, Inc.$380K
- Eisai Inc.$32K
- UCB SA$25K
- Jazz Pharmaceuticals Inc.$13K
- Zogenix Inc.$7K
- H. Lundbeck A S$3K
What the payments were for
- Consulting fees$273,76120%
- Speaking & faculty fees$924,22867%
- Travel & lodging$150,37711%
- Food & beverage$29,8842%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 798 | $615,384 |
| Jazz Pharmaceuticals Inc. | 206 | $227,699 |
| Neuropace, Inc. | 261 | $193,452 |
| SK Life Science, Inc. | 186 | $179,866 |
| Greenwich Biosciences, Inc. | 87 | $93,250 |
| Eisai Inc. | 40 | $40,825 |
| Catalyst Pharmaceuticals, Inc. | 14 | $12,031 |
| UCB SA | 3 | $11,636 |
| Sunovion Pharmaceuticals Inc. | 2 | $2,572 |
| Livanova USA, Inc. | 3 | $778 |
| Neurelis, Inc. | 5 | $337 |
| Orthofix Medical, Inc. | 1 | $134 |
| Aquestive Therapeutics, Inc. | 1 | $125 |
| Medtronic | 2 | $43 |
| Upsher-smith Laboratories LLC | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $28 |
| Zimmer Biomet | 1 | $25 |
| Otter Pharmaceuticals, LLC | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$317,252
- Briviact$256,348
- XCOPRI$157,533
- RNS Neurostimulator Kit$143,403
- Fintepla$130,174
- Nayzilam$129,576
- Fycompa$52,557
- RNS System$47,652
- Cenobamate$18,481
- Vimpat$3,651
- APTIOM$2,500
- VNS Therapy$716
- VALTOCO$223
- Trinity ELITE$134
- SYMPAZAN$125
- ZEPZELCA$124
How this compares
$1,378,262 in reported general payments places this provider in the 95th percentile of 30 epilepsy providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 535 | $944,840 |
| EpidiolexCannabidiol (Cbd) | 143 | $883,437 |
| FinteplaFenfluramine Hcl | 29 | $607,303 |
| BriviactBrivaracetam | 263 | $531,415 |
| NayzilamMidazolam | 96 | $114,131 |
| FycompaPerampanel | 55 | $87,018 |
| Lacosamide | 488 | $75,454 |
| Lamictal XrLamotrigine | 13 | $70,894 |
| VimpatLacosamide | 23 | $60,708 |
| AptiomEslicarbazepine Acetate | 20 | $56,666 |
| OnfiClobazam | 14 | $36,561 |
| LamictalLamotrigine | 24 | $28,991 |
| Clobazam | 286 | $25,549 |
| Felbamate | 46 | $14,098 |
| Levetiracetam | 168 | $9,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact, Nayzilam, Vimpat | $615,384 | $1,313,558411 claims |
| SK Life Science, Inc.Xcopri | $179,866 | $944,840535 claims |
| Eisai Inc.Fycompa | $40,825 | $87,01855 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $2,572 | $56,66620 claims |
| Upsher-smith Laboratories LLCTopiramate | $29 | $1,23874 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 epilepsy providers in Michigan.
Other epilepsy in Grand Rapids
- Evan TankGrand Rapids$28K
- Ammar KhederGrand Rapids$12K
- Charles AsburyGrand Rapids$2K
- Rachel FabrisGrand Rapids$2K
- David OrtizGrand Rapids$2K
- Philip McCarthyGrand Rapids$1K
- Luke SalbertGrand Rapids$962
- Desiree MarkantoneGrand Rapids$431
- Shan AbbasGrand Rapids$298
- Erin OkazakiGrand Rapids$260
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.